Guidant CE-marks aortoiliac graft:
This article was originally published in Clinica
Executive Summary
Guidant has gained the go-ahead to market in Europe its Ancure Aortoiliac Endograft device as a less invasive treatment for those patients with abdominal aortic aneurysms (AAA), who are ineligible for Guidant's current endovascular graft due to advanced vascular disease in the iliac arteries. The product comprises a polyester graft or tube that is inserted through an incision in the groin and attached to the aorta with tiny metal hooks. This reinforces the aorta wall. The Indianapolis, Indiana firm plans to introduce the latest product in its line of aortic grafting devices in the US this year, pending FDA approval.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.